Immatics N.V.
NASDAQ Capital MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Harpreet Singh
- Full Time Employees
- 554
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- Paul-Ehrlich-Strasse 15 Tübingen Germany 72076
- IPO Date
- Dec 12, 2018
- CIK
- 0001809196
- Website
- immatics.com
- Similar Companies
- Business
- Immatics N.V. (Nasdaq: IMTX) is a clinical-stage biopharmaceutical company focused on the discovery and development of T cell redirecting immunotherapies targeting solid tumors, particularly those expressing the PRAME antigen prevalent in more than 50 cancers; its two primary therapeutic modalities comprise TCR-engineered adoptive cell therapies (ACT), including the lead candidate IMA203 (PRAME-targeted TCR-T for advanced melanoma in Phase 3 SUPRAME trial) and IMA203CD8, and TCR Bispecifics such as IMA401 (MAGEA4/8-targeted), IMA402 (PRAME-targeted in Phase 1b expansions), and earlier-stage programs. Founded in 2000 as a spin-off from the University of Tuebingen's Institute of Immunology, the company maintains its corporate seat in Amsterdam, Netherlands, with primary operations and headquarters in Tuebingen, Germany, and additional facilities in Munich, Germany, and Houston, Texas, USA, employing approximately 700 team members across three global sites. Immatics leverages proprietary technology platforms for target discovery (over 200 tumor-associated targets identified) and TCR development, serving advanced solid tumor patients through four active clinical programs in cutaneous melanoma, uveal melanoma, and other refractory solid tumors. Recent developments include the ongoing Phase 3 SUPRAME trial initiation for IMA203 with first patient randomized in 2024 and enrollment targeted for completion in 2026; expansion of Phase 1b trials for IMA203CD8, IMA402, and IMA401 with clinical updates anticipated in Q4 2025; strategic research collaborations with Moderna (2022, spanning bispecifics, cell therapy, and vaccines), Bristol Myers Squibb (revenue-generating since 2015), Editas Medicine (2019, gene editing for gamma delta T cells), and MD Anderson Cancer Center; appointment of a new CFO from Anthos Therapeutics in late 2025 to support commercial preparation for IMA203 launch; and priming of in-house manufacturing facilities for late-stage clinical and commercial supply of TCR-T therapies.
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Immatics Presents Clinical Activity and Response Dynamics of Anzu-cel PRAME Cell Therapy at 2026 ASCO Annual Meeting
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
Immatics Presents Data on IMA401 MAGEA4/8 Bispecific at 2026 ASCO Annual Meeting with Simultaneous Publication in Nature Medicine Supporting Development of IMA401/IMA402 Combination in Lung Cancer
Immatics Presents Clinical Activity of IMA203CD8 PRAME Cell Therapy in Hard-to-Treat Gynecologic Cancers at 2026 ASCO Annual Meeting
Immatics (IMTX) Reports Q1 Loss, Lags Revenue Estimates
Immatics Announces First Quarter 2026 Financial Results and Business Update
All You Need to Know About Immatics (IMTX) Rating Upgrade to Buy
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
Immatics Announces Four Upcoming Oral Presentations Across Its Clinical Cell Therapy and Bispecific Portfolio at 2026 ASCO Annual Meeting
PRAME-directed Cell Therapy Using Immatics’ TCR Induces Deep and Durable Remission in Pediatric Patient with Advanced Metastatic Nephroblastoma
SG Americas Securities LLC Makes New Investment in Immatics N.V. $IMTX
Immatics N.V. (NASDAQ:IMTX) Receives $19.00 Average PT from Analysts
Immatics: Buying The Anzu-Cel Floor, Playing The Moderna Moonshot
Immatics (NASDAQ:IMTX) Trading Down 5% – Here’s What Happened
Immatics N.V. (NASDAQ:IMTX) Receives Average Recommendation of “Moderate Buy” from Analysts
Immatics (NASDAQ:IMTX) Stock Price Up 3.9% – Should You Buy?
Immatics: PRAME Leader's Transition To Commercial Reality
Immatics Presents IMA203CD8 PRAME Cell Therapy Data from Ongoing Dose Escalation and Shows Promising Initial Anti-tumor Activity in PRAME-Positive Tumors at ESMO-IO 2025 Congress
Immatics Announces $125 Million Underwritten Offering